koryu

Editas bear trap

Длинная
koryu Обновлено   
NASDAQ:EDIT   Editas Medicine, Inc.
8
i am still long EDIT from 13$, 16$ and $21 holding my long term positions.

But need to switch from log to linear scale here to find the support, this current dump seems like a bear trap to shake out the weak hands who bought into the patent news hype. smart money has taken profit on double up causing the first sell off.
If the linear trendline is broken down we have to expect a longer correction phase with support at 18$, 16$ and 13$. Below 12.50 is very unlikely and would require a major fundamental change.

I expect smart money to buy back before the next coming media attention and that we are still in the first awareness phase.

my target over the next years is 63$ ~ 2b cap

The bearish scenario is that this is a b wave and we go for an impulsiv c down to 2-10$, but at 10$ we would have a company value of below 500m... Very unlikely because this would allow people to enter below the price that the venture capital like google ventures and bill gates entered EDIT. These firms would likely add up and defend their long position in this promising company.
Сделка активна:
increased position $19.40
Комментарий:
Bear trap was more painful as expected but price back above IPO Level.
Added a little more in the $18 range.

Media attention is kicking in on crispr as first human embryo was crispr'd in the United States.
Комментарий:
Chart has formed a giant W-bottom. Long term looks pretty good.
Some news:

Improved accuracy
phys.org/news/2017-0...rispr-cas9-gene.html

Feng Zhang receives MIT $500k innovation prize for CRSPR invention
www.bizjournals.com/...pr-gene-editing.html
Комментарий:
it took a little bit longer, chart updated
Комментарий:
This first cycle is completed.
The next will start with the breakout:
Комментарий:

Отказ от ответственности

Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.